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Breed Differences in Natriuretic Peptides in Healthy Dogs
K. Sj€ostrand, G. Wess, I. Ljungvall, J. H€aggstr€om, A-C. Merveille, M. Wiberg, V. Gouni, J. Lundgren
Willesen, S. Hanas, A-S. Lequarre, L. Mejer Sørensen, J. Wolf, L. Tiret, M. Kierczak, S. Forsberg,
K. McEntee, G. Battaille, E. Sepp€al€a, K. Lindblad-Toh, M. Georges, Hannes Lohi, V. Chetboul,
M. Fredholm, and K. H€oglund
Background: Measurement of plasma concentration of natriuretic peptides (NPs) is suggested to be of value in diagnosis of
cardiac disease in dogs, but many factors other than cardiac status may influence their concentrations. Dog breed potentially is
1 such factor.
Objective: To investigate breed variation in plasma concentrations of pro-atrial natriuretic peptide 31-67 (proANP 31-67)
and N-terminal B-type natriuretic peptide (NT-proBNP) in healthy dogs.
Animals: 535 healthy, privately owned dogs of 9 breeds were examined at 5 centers as part of the European Union (EU)
LUPA project.
Methods: Absence of cardiovascular disease or other clinically relevant organ-related or systemic disease was ensured by
thorough clinical investigation. Plasma concentrations of proANP 31-67 and NT-proBNP were measured by commercially avail-
able ELISA assays.
Results: Overall significant breed differences were found in proANP 31-67 (P < .0001) and NT-proBNP (P < .0001) concen-
trations. Pair-wise comparisons between breeds differed in approximately 50% of comparisons for proANP 31-67 as well as NT-
proBNP concentrations, both when including all centers and within each center. Interquartile range was large for many breeds,
especially for NT-proBNP. Among included breeds, Labrador Retrievers and Newfoundlands had highest median NT-proBNP
concentrations with concentrations 3 times as high as those of Dachshunds. German Shepherds and Cavalier King Charles Span-
iels had the highest median proANP 31-67 concentrations, twice the median concentration in Doberman Pinschers.
Conclusions and Clinical Importance: Considerable interbreed variation in plasma NP concentrations was found in healthy
dogs. Intrabreed variation was large in several breeds, especially for NT-proBNP. Additional studies are needed to establish
breed-specific reference ranges.
Key words: Canine; Interbreed variation; Intrabreed variation; NT-proBNP; Plasma; proANP 31-67.
Natriuretic peptides (NPs) are used as indicators ofcardiac health in humans and have been sug-
gested to be of diagnostic and prognostic value in car-
diac disease in dogs. B-type natriuretic peptide (BNP)
and N-terminal pro-B-type natriuretic peptide (NT-
proBNP) tests currently are widely used as diagnostic
and prognostic tools for congestive heart failure
(CHF) and left ventricular dysfunction in acute myo-
cardial infarction in humans.1 Increased plasma NP
concentrations have been identified in dogs with
dilated cardiomyopathy (DCM).2–7 Furthermore, NP
concentrations have been shown to increase with
increasing disease severity in dogs with myxomatous
mitral valve disease (MMVD),3,8–11 and NT-proBNP
has been suggested to be predictive of outcome in dogs
with MMVD.9,12–16 Natriuretic peptides also have
been found useful to distinguish CHF from respiratory
disease.12,17–20 However, in several studies of dogs,
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considerable overlap between investigated groups has
been identified.2,3,8,9,11,17–19
Both atrial natriuretic peptide (ANP) and B-type natri-
uretic peptide (BNP) are synthesized as high-molecular
weight precursors (prohormones), which are cleaved into
2 segments21,22; 1 biologically active peptide in the C-ter-
minal region described as ANP or BNP, and 1 biologi-
cally inactive N-terminal segment described as NT-
proANP or NT-proBNP.1,21–23 NT-proANP is further
cleaved into 3 segments; proANP 1-30, 31-67, and 68-
98.24 All segments can be analyzed,3,4,6,8,17,18,25 but the
N-terminal segments have been found to have longer
half-lives and may, therefore, be better suited as diagnos-
tic tools.11,26–29 Furthermore, midregional proANP, such
as proANP 31-67, has been shown to have high biologi-
cal stability, potentially because of a lower risk of frag-
mentation compared to proANP 1-98.27
A clinically useful diagnostic and prognostic test for
canine heart disease requires an upper reference limit for
natriuretic peptides in healthy dogs, and cutoff values for
dogs with subclinical disease or clinical signs of
CHF.29,30 There are, however, numerous physiologic
and pathologic factors in addition to cardiac function
that may influence NP concentrations in humans as well
as dogs, and concerns exist about how to adjust reference
limits and cutoff-values with regard to these fac-
tors.3,6,8,9,17–19,30–32
Previous studies have indicated potential breed dif-
ferences in NP concentrations,3,4,18 and differences
have been shown in concentration of NT-proBNP
between healthy purebred and healthy mixed breed
dogs.3 To our knowledge, the influence of breed on
NP concentration has not been specifically studied pre-
viously. Hence, the aim of this study was to investigate
breed variation in the plasma concentrations of
proANP 31-67 and NT-proBNP in healthy dogs.
Materials and Methods
Animals
Dogs were examined at 5 centers, as part of the EU-funded
LUPA project.33 Centers included University of Liege, Belgium;
University of Copenhagen, Denmark; National Veterinary School
of Alfort, France; University of Helsinki, Finland, and the Swed-
ish University of Agricultural Sciences, Sweden. The study was
approved by an ethical committee in each participating country.
Dogs were privately owned, and informed owner consent was
obtained. To be included in the study, dogs had to be purebred,
healthy, and between 1 and 7 years of age. They also had to have
a normal body condition score, and could not be related to each
other at parental level. Each center could only include 2–5
breeds, and within center, each breed cohort included dogs of 1
sex only, intact males or females that were spayed or in anestrus,
according to the inclusion criteria of the LUPA project. One
breed was represented at 4 out of 5 centers. Exclusion criteria
consisted of any finding indicating systemic or organ-related dis-
ease observed during the clinical examination described below.
Preparations
Dog owners were instructed to feed their dog only standard
commercial dog food 2 weeks before participation in the study to
ensure consistent salt intake. On examination day, all dogs were
fasted and had no access to water for at least 2 hours before the
examination.
Verification of Health Status
Each dog underwent a general physical examination including
blood pressure measurement by high-definition oscillometry, a
5-minute ECG recording, and an echocardiographic examination.
The echocardiographic examination was performed from the
right and left sides, by using standardized imaging planes34 and
continuous ECG monitoring. The left atrial-to-aortic root ratio
was quantified from the right 2-dimensional short-axis view.35
Pulmonic and aortic flow velocities were measured by spectral
Doppler, and the mitral, aortic, pulmonic, and tricuspid valves
were screened with color Doppler. The left ventricle was mea-
sured by standard M-mode techniques. All examinations were
performed in unsedated dogs.
Sampling Procedures and Storage
Urine samples were collected by voiding and standard urine
analysis was performed by dipstick chemistry test, and refractom-
eter for urine specific gravity. Blood sampling was carried out by
venipuncture, and blood was collected into 5-mL EDTA and
serum tubes. Routine analysis of hematology and biochemistry
including parameters of liver and kidney function, glucose, and
serum electrolyte concentrations were performed for verification
of health status. EDTA tubes for analysis of natriuretic peptides
were centrifuged within 30 minutes of blood sample collection.
Plasma was harvested, transferred into plastic cryotubes, and
samples were frozen and stored at 80°C. For practical reasons,
at 1 center samples were stored at 20°C for a maximum of
2 weeks, after which they were transferred frozen to 80°C and
stored for batched analysis. Previous studies have shown that
midregional proANP is stable for 3–6 months at 20°C and NT-
proBNP is stable for 4 months at 20°C.27,36,37 All samples were
later transported frozen to 2 accredited laboratories, 1 laboratory
for analysis of proANP 31-67 and another laboratory for analy-
sis of NT-proBNP. Protease inhibition was not employed in this
study.
Analysis of Natriuretic Peptides
Plasma concentrations of proANP 31-67 and NT-proBNP
were analyzed by commercially available ELISA assays, accord-
ing to manufacturers’ instructions.,a,b All samples were analyzed
in duplicate by personnel blinded to dog identity, and the mean
of the 2 results was used for data analysis. Both assays have been
validated for dogs.17,38
Statistical Analyses
Commercially available softwarec was used for all statistical
analyses. Data are presented as medians and interquartile ranges
(IQR). A value of P < .05 was considered significant for the
analyses, unless otherwise indicated.
The nonparametric Kruskal–Wallis test was used to investi-
gate overall differences among breeds, for concentrations of pro-
ANP 31-67 and NT-proBNP, respectively. If a significant
difference was detected, pair-wise comparisons between breeds
were performed by use of the Mann–Whitney U-test with
Bonferroni adjustment, for which a value of P < .0014 was con-
sidered significant. The Kruskal–Wallis test also was used to
investigate differences among breeds at each center for concen-
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trations of proANP 31-67 and NT-proBNP, respectively. At
centers including more than 2 breeds, pair-wise comparisons
between breeds were performed by use of the Mann–Whitney U-
test with Bonferroni adjustment, if an overall significant differ-
ence was detected.
Interquartile distances were calculated for all dogs as well as
per breed for each NP, by subtracting the 25-percentile value
from the 75-percentile value. Interquartile distances were cor-
rected for differences in median values by dividing the interquar-
tile distance by the median value for all dogs as well as per breed
for each NP.
Unilinear regression analyses were performed to evaluate
potential associations between breed as well as age, body weight,
examination center, and concentrations of proANP 31-67 and
NT-proBNP, respectively. A subanalysis of the same variables by
unilinear regression analysis was performed in the Labrador
Retriever breed alone, because this breed included the largest
number of dogs, was represented at 4 out of 5 centers and
included both female and male dogs. Therefore, sex also was
assessed by unilinear regression analysis in the Labrador Retrie-
ver breed.
To compensate for the influence of other confounding factors
on plasma NP concentrations, a multiple regression analysis was
performed, including variables that reached P < .2 in the unilin-
ear regression analysis of all dogs. Analyses were performed in a
reverse stepwise manner,39 starting with all variables included in
the model and then removing the variable with the highest P
value until all remaining variables had a value of P < .05. All
variables were assessed only as main effects; no interaction terms
were considered in the model.
The distribution of residuals in the multiple regression analysis
was tested for normality by Shapiro–Wilk W-test. The adjusted
R2 is defined as the percentage of the total sum of squares that
can be explained by the regression and it also considers the
degrees of freedom for variables added. No multiple regression
analysis was performed in the Labrador Retriever cohort attrib-
utable to the high covariance between center and sex.
Results
In total, 535 dogs of 9 breeds were included in the
study. These dogs had passed the general health exam-
ination without abnormal findings, no ECG abnor-
malities were detected, and all echocardiographic
variables were within the reference range. Further-
more, no clinically relevant abnormalities were
detected in the hematologic or serum biochemistry
variables or in the urine analysis. Distribution of
breeds and individuals examined at the different cen-
ters is shown in Table 1. Each center examined dogs
belonging to 2–4 different breeds; some breeds were
examined at more than 1 center. Sex distribution was
uneven with 416 males and 119 female dogs (Table 1).
All males were intact whereas females were spayed or
in anestrus. Median age (n = 531) was 3.3 (IQR, 2.6–
4.4) years and median body weight (n = 497) was 30.2
(IQR, 23.5–36.0) kg.
Natriuretic Peptides
The median concentration of proANP 31-67
(n = 535) was 889 (IQR, 735–1,065) pmol/L, whereas
the median concentration of NT-proBNP (n = 527)
was 638 (IQR, 403–980) pmol/L. Natriuretic peptide
concentrations by breed are shown in Figure 1. The
overall interquartile distance was 330 pmol/L for pro-
ANP 31-67 and 577 pmol/L for NT-proBNP. Overall
interquartile distance median ratio was 0.37 for
proANP 31-67 and 0.90 for NT-proBNP.
Group-Wise Comparisons, All Dogs. There was an
overall significant breed difference for proANP 31-67
(P < .0001) and NT-proBNP (P < .0001). Pair-wise
comparisons between breeds showed significant differ-
ences in 15 of 36 comparisons of proANP 31-67 and
18 of 36 comparisons of NT-proBNP (Table 2). Con-
centrations of proANP 31-67 were lowest in Dober-
man Pinschers, with a median concentration almost
half of the median values in German Shepherds and
Cavalier King Charles Spaniels, which had the highest
concentrations. Concentrations of NT-proBNP were
lowest in Dachshunds, whereas Labrador Retrievers
and Newfoundlands had the highest concentrations
with median values 3 times the median value in Dachs-
hunds (Fig 1). Interquartile distances and interquartile
distance median ratios per breed for both NPs are
shown in Figures 2 and 3.
Group-Wise Comparisons, within Center. Overall sig-
nificant breed differences were found at 3 of the 5 cen-
ters for proANP 31-67 (P ≤ .0006) and at 4 of the 5
centers for NT-proBNP (P < .003). Pair-wise compari-
sons showed significant differences in 8 of 16 compari-
sons of proANP 31-67 and 7 of 16 comparisons of
NT-proBNP.
Unilinear Regression Analysis. In the unilinear
regression analysis of all dogs, an association was
shown between proANP 31-67 and breed (R2 = 0.15,
P < .0001) as well as center of examination (R2 = 0.07,
P < .0001). NT-proBNP also was associated with
breed (R2 = 0.16, P < .0001) and center of examina-
tion (R2 = 0.16, P < .0001). Furthermore, NT-proBNP
concentration increased with increasing body weight
(R2 = 0.04, P < .0001). In the separate unilinear
regression analysis of Labrador Retrievers, an associa-
tion was shown between proANP 31-67 and center of
examination (R2 = 0.11, P = .003) as well as sex
Table 1. Distribution by center of examination,
breed, and sex.
Belgium Denmark Finland France Sweden Total
Box 15M 15
BS 97M 26M 123
CKCS 34M 34
Dach 26M 16M 42
Dob 25M 25
FinL 50M 50
GS 16M 60M 76
Lab 6M 45F 29F 45M 125
NF 45F 45
Total 119 90 136 80 110 535
Box, Boxer; BS, Belgian Shepherd; CKCS, Cavalier King
Charles Spaniel; Dach, Dachshund; Dob, Doberman Pinscher;
FinL, Finnish Lapphund; GS, German Shepherd; Lab, Labrador
Retriever; NF, Newfoundland; M, male; F, female.
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(R2 = 0.05, P = .013), with higher concentrations in
male than female dogs. In Labrador Retrievers, NT-
proBNP was associated with center of examination
(R2 = 0.24, P < .0001) and sex (R2 = 0.24, P < .0001),
with higher concentrations in female than male dogs.
Multiple Regression Analysis. The multiple regres-
sion analysis of all dogs confirmed an effect of breed
(P < .0001) and center (P = .0008) on proANP 31-67
concentration with an adjusted model R2 of 0.16. Also
for NT-proBNP concentration, multiple regression
analysis confirmed an effect of breed (P < .0001) and
center (P < .0001) with an adjusted model R2 of 0.22.
Discussion
Highly significant overall breed differences were
found in plasma concentrations of proANP 31-67 and
NT-proBNP in healthy dogs examined at 5 centers.
Differences were found in approximately 50% of the
pair-wise comparisons between breeds for proANP
31-67 as well as NT-proBNP concentrations, both
when including all centers and within each center, sug-
gesting that the differences were of genuine clinical
importance.
Included breeds represented dogs of varying body
sizes, temperament, use and genetic background.
Strong selection for certain physiologic, morphologic
and behavioral traits has created dog breeds with a
unique diversity among mammalian species, and spe-
cific features are inherited closely within breeds.40
Among the 9 included breeds, Labrador Retrievers
and Newfoundlands had the highest median NT-proB-
NP concentrations with values 3 times as high as those
in Dachshunds. The median proANP 31-67 concentra-
tion instead was highest in German Shepherds and
CKCSs, with median concentrations twice the median
concentration in Doberman Pinschers. The breed vari-
ation could partly be explained by genetic background,
as illustrated by the closely related breeds, German
and Belgian Shepherds, having very similar distribu-
tions of both proANP 31-67 and NT-proBNP. Previ-
ous studies have shown breed differences in
cardiovascular variables such as blood pressure, heart
rate, and catecholamine concentrations.41–43 Tachycar-
dia has been associated with increased plasma concen-
trations of ANP in people as well as in dogs and has
been suggested to depend primarily on increased atrial
pressure.44,45 Both ANP and BNP are released in
response to volume expansion and pressure overload.
However, their modes of production and release differ,
with proANP being stored intact in secretory granules,
whereas BNP is constitutively secreted and has little
intracellular storage. In healthy dogs, both ANP and
BNP are produced in the atria, whereas ventricles as
well as atria contribute to the production of ANP and
BNP in dogs with CHF.46,47
All dogs included in this study were confirmed to be
healthy by an extensive health examination. Most
breeds had higher concentrations of proANP 31-67
than NT-proBNP, which is consistent with recent find-
ings in healthy people.27,48 The interquartile distance
was large in several breeds, especially for NT-proBNP,
with 32% of the total number of dogs having NT-
proBNP concentrations higher than a previously
proposed value indicative of heart disease in dogs.30
Sample handling differed slightly, with protease inhibi-
tors being used in the previous study, and not in this
study, but the same assay was used in both studies. A
high individual weekly variability in NT-proBNP con-
centration has been shown in healthy dogs,32 making
interpretation of a single individual sample uncertain.
The lower variability for proANP 31-67 in combina-
tion with high biologic stability, attributable to low






































































Fig 1. Boxplots showing distribution of proANP 31-67 (A) and
NT-proBNP (B) by breed. The top, bottom, and line through the
middle of each box correspond to the 75th percentile (top quar-
tile), the 25th percentile (bottom quartile) and the 50th percentile
(median), respectively. The whiskers extend from the bottom
2.5th percentile to the top 97.5th percentile. Outliers, which are
represented by black dots, were included in the statistical analy-
ses. There was an overall significant difference between breeds for
both natriuretic peptides (P < .0001). For information on which
breeds that differed significantly, see Table 2. Box, Boxer; BS,
Belgian Shepherd; CKCS, Cavalier King Charles Spaniel; Dach,
Dachshund; Dob, Doberman Pinscher; Fin L, Finnish Lapp-
hund; GS, German Shepherd; Lab, Labrador Retriever; NF,
Newfoundland.
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molecule for further studies in dogs. Comparing con-
centrations of proANP 31-67 in this study to the previ-
ously proposed cutoff value of 1,750 pmol/L for CHF
in dogs,49 <1% of our included healthy dogs were
above the cutoff.
Center of examination was associated with plasma
concentration of both proANP 31-67 and NT-proBNP
in both unilinear and multiple regression analyses.
Because of the uneven breed distribution among cen-
ters, breed was highly covariate with center. Therefore,
group-wise comparisons between breeds also were per-
formed at each center. The results showed a similar
percentage of significant pair-wise differences as
observed when all dogs were included (approximately
50% for both NPs), confirming the presence of breed
variation in the examined population.
Because of the uneven sex distribution among centers
as well as breeds, sex was not included in the unilinear
or multiple regression analyses of all dogs. In the unilin-
ear regression analysis of the Labrador Retriever
cohort, an association between sex and NT-proBNP
concentration was found, with higher concentrations in
females compared to males, a finding that also has been
made in healthy people.48 A weak association also was
found between sex and concentration of proANP 31-67,
with higher concentrations in males compared to
females. This study was, however, not designed to eval-
uate sex differences and no multiple regression analysis
was performed in the Labrador Retriever cohort,
because of the high covariance between center and sex.
Additional study into the potential effect of sex on NP
concentrations in dogs is warranted.
A strong association between age and NP concentra-
tions has been found in several large studies of
humans,31 a finding potentially caused by decreased
Table 2. Pair-wise comparisons between breeds in plasma concentrations of the natriuretic peptides proANP 31-
67 and NT-proBNP. The asterisks denote significant differences by using a Bonferroni corrected P value of <.014.
Box CKCS Dach Dob FinL GS Lab NF
BS – – – * – * – – proANP 31-67
– – * – – – * * NT-proBNP
– Box * – – – * – – proANP 31-67
* – – – * * NT-proBNP
– – CKCS * * – – – – proANP 31-67
– * – – – * * NT-proBNP
– – – Dach * * * * * proANP 31-67
– – – * * * * NT-proBNP
– – – – Dob * * * * proANP 31-67
– – – – – * * NT-proBNP
– – – – – FinL – – – proANP 31-67
– – – – – * * NT-proBNP
– – – – – – GS – – proANP 31-67
– – – – – * – NT-proBNP
– – – – – – – Lab – proANP 31-67
– – – – – – – NT-proBNP
Box, Boxer; BS, Belgian Shepherd; CKCS, Cavalier King Charles Spaniel; Dach, Dachshund; Dob, Doberman Pinscher; FinL, Finn-


































Fig 2. Interquartile distances of NT-proBNP and proANP 31-
67 displayed by breed. Box, Boxer; BS, Belgian Shepherd; CKCS,
Cavalier King Charles Spaniel; Dach, Dachshund; Dob, Dober-
man Pinscher; Fin Lap, Finnish Lapphund; GS, German Shep-
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Fig 3. Interquartile distances corrected for median values of
NT-proBNP and proANP 31-67 displayed by breed. Box, Boxer;
BS, Belgian Shepherd; CKCS, Cavalier King Charles Spaniel;
Dach, Dachshund; Dob, Doberman Pinscher; Fin Lap, Finnish
Lapphund; GS, German Shepherd; Lab, Labrador Retriever;
NF, Newfoundland.
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heart function with greater age. In healthy dogs, NT-
proANP has been shown to be positively associated
with age in a small study,50 whereas BNP has been
shown to be positively associated with age in dogs
with CHF, potentially attributable to the higher inci-
dence of heart disease in older male dogs.18 In this
study, no association between age and NP concentra-
tion was found. However, the study only included
young adult to middle-aged dogs, and additional stud-
ies are needed to investigate a potential association
between age and proANP 31-67 and NT-proBNP in
healthy dogs.
Study Limitations
The study only included 9 breeds and, therefore,
cannot be considered representative of the entire dog
population. Because of the uneven sex representation
and narrow age span of included dogs, results should
not be interpreted as reference values. To establish
reference values, additional studies evaluating other
breeds with an even sex and age representation
should be performed. Blood was collected only once
from each dog. Therefore, individual variability in
NP concentrations could not be assessed. The compa-
rably low R2-values of the final multiple regression
models for both NPs suggest that factors other than
breed and center affect NP concentrations, with 1
potential factor being individual variation.32 All dogs
were fed commercial dog food, but differences in salt
intake could have occurred, potentially affecting NP
concentrations. Sample handling was standardized,
although minor differences in short-term freezing
temperature occurred at 1 center. However, NPs have
been shown to be stable at the freezing temperatures
used,27,36,37 and each peptide was analyzed in batches
at the same laboratory. Hence, it is unlikely that
sample handling had any major effect on the results.
Conclusion
Considerable breed variation exists in concentrations
of proANP 31-67 and NT-proBNP in healthy dogs.
Intrabreed variation was large in several breeds, espe-
cially for NT-proBNP. Additional studies are war-
ranted to establish breed-specific reference values, in
order to improve future use of natriuretic peptides as
cardiac biomarkers in dogs.
Footnotes
a ProANP 31-67: ELISA VETSIGN Canine CardioSCREEN,
Biomedica, Vienna, Austria
b NT-proBNP: ELISA Cardiopet proBNP test, IDEXX Labora-
tories, Westbrook, ME
c JMP, version 9.0.0, SAS Institute Inc, Cary, NC
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